Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
EmapalumabThe purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment. Lupus Phase 3 À vérifier United States, Belgium, Canada, China, Czechia, France, Germany, Italy, … À vérifier
EmapalumabThe purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment. Lupus Phase 3 À vérifier United States, Belgium, Canada, China, Czechia, France, Germany, Italy, Japan, Netherlands, Poland, Spain, United Kingdom À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Emapalumab Lupus Phase 3 NCT05001737 EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE COMPLETED

Publications

3
MoléculeIndication / populationTitreJournalDate
Emapalumab Retrospective study on allogeneic hematopoietic stem cell transplantation for the treatment of Hemophagocytic lymphohistiocytosis. Transplant immunology
Emapalumab Living Donor Liver Transplantation as Salvage Therapy for Steroid-Refractory Chronic Hepatic GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation. Pediatric transplantation
Emapalumab Emapalumab for the Treatment of Peri-Graft Hemophagocytic Lymphohistiocytosis Reactivation in a Patient With Familial Hemophagocytic Lymphohistiocytosis Type 3. Pediatric blood & cancer